Company news

Evofem Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

June 26, 2024

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

June 10, 2024

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

May 14, 2024

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

April 17, 2024

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

March 26, 2024

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

March 19, 2024

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

March 6, 2024

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

January 31, 2024

Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game

January 7, 2024

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

December 11, 2023

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023

November 13, 2023

Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023

October 23, 2023

Evofem to Participate in the Virtual Investor Ask the CEO Conference

October 12, 2023

Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire

September 26, 2023

Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor

September 10, 2023

Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange

August 21, 2023

Evofem Biosciences Announces Financial Results for the Second Quarter of 2023

August 13, 2023

Evofem to Participate in the Virtual Investor Summer Spotlight Series

July 5, 2023

Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023

May 31, 2023

Evofem Biosciences Announces 1-for-125 Reverse Stock Split

May 16, 2023

Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update

April 27, 2023

Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

April 13, 2023

Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required

April 11, 2023

Evofem Biosciences Announces Cost Reduction Measures

March 20, 2023

Evofem Biosciences Appoints Interim Chief Financial Officer

March 8, 2023

Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering

February 28, 2023

Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi

February 27, 2023

Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value

February 23, 2023

Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)

January 12, 2023

Costco Adds Phexxi® to Member Prescription Program

January 10, 2023

Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women

January 9, 2023

OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022

December 29, 2022

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

October 11, 2022

OTC Markets Group Welcomes New OTCQB Companies – October 10

October 10, 2022

Evofem Biosciences Announces Approval of Phexxi in Nigeria

October 6, 2022

Evofem Biosciences Announces Uplisting to OTCQB

October 3, 2022

← Newer news releases

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.